PMID- 33279683
OWN - NLM
STAT- MEDLINE
DCOM- 20210705
LR  - 20220531
IS  - 2213-7173 (Electronic)
IS  - 2213-7165 (Linking)
VI  - 24
DP  - 2021 Mar
TI  - Efficacy and safety of dalbavancin in the treatment of Gram-positive bacterial 
      infections.
PG  - 72-80
LID - S2213-7165(20)30304-0 [pii]
LID - 10.1016/j.jgar.2020.11.018 [doi]
AB  - OBJECTIVES: In this meta-analysis, we assessed the clinical efficacy and safety 
      of dalbavancin compared with commonly used anti-Gram-positive agents. METHODS: 
      PubMed, Embase and Cochrane Library databases were searched from inception up to 
      25 February 2020. Randomised controlled trials (RCTs) comparing the efficacy and 
      safety of dalbavancin with other antibiotics against Gram-positive infections 
      were included. Reviews, conference abstracts, editorials, case reports, studies 
      on healthy people, or those lacking a comparator group or focusing on different 
      dosages were excluded. RESULTS: Seven RCTs comprising 2665 patients were 
      included. Five RCTs included 2109 patients with skin and skin-structure 
      infections (SSSIs) and the other two included patients with catheter-related 
      bloodstream infections (CRBSIs) and osteomyelitis, respectively. Clinical and 
      microbiological responses to dalbavancin were similar to other antibiotics in 
      treating infections caused by Gram-positive bacteria, including the SSSI 
      subgroup. Clinical response to dalbavancin showed superiority in the CRBSI and 
      osteomyelitis subgroups. No significant difference was observed between 
      dalbavancin and other treatments in terms of adverse events (AEs), adverse drug 
      reactions (ADRs) and serious AEs. However, the single-dose regimen had 
      significantly more AEs compared with the comparator group, while the dual-dose 
      regimen resulted in fewer AEs and ADRs and a lower incidence of diarrhoea 
      compared with the comparator group. Moreover, the dalbavancin group showed a 
      decreased mortality risk compared with other treatments. CONCLUSION: Dalbavancin 
      was comparable with other antibiotics in treating chronic Gram-positive 
      infections in terms of efficacy and safety. The dual-dose regimen showed a better 
      safety profile compared with the single-dose regimen in the treatment of SSSIs.
CI  - Copyright (c) 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
FAU - Wang, Yuhang
AU  - Wang Y
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, Beijing, China.
FAU - Wang, Jin
AU  - Wang J
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, Beijing, China.
FAU - Wang, Rui
AU  - Wang R
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, Beijing, China.
FAU - Li, Yuanyuan
AU  - Li Y
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, Beijing, China.
FAU - Cai, Yun
AU  - Cai Y
AD  - Center of Medicine Clinical Research, Department of Pharmacy, PLA General 
      Hospital, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20201203
PL  - Netherlands
TA  - J Glob Antimicrob Resist
JT  - Journal of global antimicrobial resistance
JID - 101622459
RN  - 0 (Anti-Bacterial Agents)
RN  - 61036-62-2 (Teicoplanin)
RN  - 808UI9MS5K (dalbavancin)
SB  - IM
MH  - Anti-Bacterial Agents/adverse effects
MH  - *Gram-Positive Bacterial Infections/drug therapy
MH  - Humans
MH  - *Skin Diseases, Bacterial/drug therapy
MH  - Teicoplanin/adverse effects/analogs & derivatives
OTO - NOTNLM
OT  - Catheter-related bloodstream infection
OT  - Dalbavancin
OT  - Meta-analysis
OT  - Osteomyelitis
OT  - Skin and skin-structure infection
EDAT- 2020/12/07 06:00
MHDA- 2021/07/06 06:00
CRDT- 2020/12/06 20:44
PHST- 2020/05/27 00:00 [received]
PHST- 2020/10/13 00:00 [revised]
PHST- 2020/11/17 00:00 [accepted]
PHST- 2020/12/07 06:00 [pubmed]
PHST- 2021/07/06 06:00 [medline]
PHST- 2020/12/06 20:44 [entrez]
AID - S2213-7165(20)30304-0 [pii]
AID - 10.1016/j.jgar.2020.11.018 [doi]
PST - ppublish
SO  - J Glob Antimicrob Resist. 2021 Mar;24:72-80. doi: 10.1016/j.jgar.2020.11.018. 
      Epub 2020 Dec 3.